ASFP (Artificial Intelligence based Scoring Function Platform): a web server for the development of customized scoring functions

Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects

Computer-aided drug discovery and design involve the use of information technologies to identify and develop, on a rational ground, chemical compounds that align a set of desired physicochemical and biological properties. In its most common form, it involves the identification and/or modification of an active scaffold (or the combination of known active scaffolds), although de novo drug design from scratch is also possible. Traditionally, the drug discovery and design processes have focused on the molecular determinants of the interactions between drug candidates and their known or intended pharmacological target(s). Nevertheless, in modern times, drug discovery and design are conceived as a particularly complex multiparameter optimization task, due to the complicated, often conflicting, property requirements.This chapter provides an updated overview of in silico approaches for identifying active scaffolds and guiding the subsequent optimization process. Recent groundbreaking advances in the field have also analyzed the integration of state-of-the-art machine learning approaches in every step of the drug discovery process (from prediction of target structure to customized molecular docking scoring functions), integration of multilevel omics data, and the use of a diversity of computational approaches to assist target validation and assess plausible binding pockets.

ML-PLIC: a web platform for characterizing protein-ligand interactions and developing machine learning-based scoring functions

Cracking the entangling code of protein-ligand interaction (PLI) is of great importance to structure-based drug design and discovery. Different physical and biochemical representations can be used to describe PLI such as energy terms and interaction fingerprints, which can be analyzed by machine learning (ML) algorithms to create ML-based scoring functions (MLSFs). Here, we propose the ML-based PLI capturer (ML-PLIC), a web platform that automatically characterizes PLI and generates MLSFs to identify the potential binders of a specific protein target through virtual screening (VS). ML-PLIC comprises five modules, including Docking for ligand docking, Descriptors for PLI generation, Modeling for MLSF training, Screening for VS and Pipeline for the integration of the aforementioned functions. We validated the MLSFs constructed by ML-PLIC in three benchmark datasets (Directory of Useful Decoys-Enhanced, Active as Decoys and TocoDecoy), demonstrating accuracy outperforming traditional docking tools and competitive performance to the deep learning-based SF, and provided a case study of the Serine/threonine-protein kinase WEE1 in which MLSFs were developed by using the ML-based VS pipeline in ML-PLIC. Underpinning the latest version of ML-PLIC is a powerful platform that incorporates physical and biological knowledge about PLI, leveraging PLI characterization and MLSF generation into the design of structure-based VS pipeline. The ML-PLIC web platform is now freely available at http://cadd.zju.edu.cn/plic/.

TB-IECS: an accurate machine learning-based scoring function for virtual screening

Machine learning-based scoring functions (MLSFs) have shown potential for improving virtual screening capabilities over classical scoring functions (SFs). Due to the high computational cost in the process of feature generation, the numbers of descriptors used in MLSFs and the characterization of protein-ligand interactions are always limited, which may affect the overall accuracy and efficiency. Here, we propose a new SF called TB-IECS (theory-based interaction energy component score), which combines energy terms from Smina and NNScore version 2, and utilizes the eXtreme Gradient Boosting (XGBoost) algorithm for model training. In this study, the energy terms decomposed from 15 traditional SFs were firstly categorized based on their formulas and physicochemical principles, and 324 feature combinations were generated accordingly. Five best feature combinations were selected for further evaluation of the model performance in regard to the selection of feature vectors with various length, interaction types and ML algorithms. The virtual screening power of TB-IECS was assessed on the datasets of DUD-E and LIT-PCBA, as well as seven target-specific datasets from the ChemDiv database. The results showed that TB-IECS outperformed classical SFs including Glide SP and Dock, and effectively balanced the efficiency and accuracy for practical virtual screening.

Determination of Molecule Category of Ligands Targeting the Ligand-Binding Pocket of Nuclear Receptors with Structural Elucidation and Machine Learning

The mechanism of transcriptional activation/repression of the nuclear receptors (NRs) involves two main conformations of the NR protein, namely, the active (agonistic) and inactive (antagonistic) conformations. Binding of agonists or antagonists to the ligand-binding pocket (LBP) of NRs can regulate the downstream signaling pathways with different physiological effects. However, it is still hard to determine the molecular type of a LBP-bound ligand because both the agonists and antagonists bind to the same position of the protein. Therefore, it is necessary to develop precise and efficient methods to facilitate the discrimination of agonists and antagonists targeting the LBP of NRs. Here, combining structural and energetic analyses with machine-learning (ML) algorithms, we constructed a series of structure-based ML models to determine the molecular category of the LBP-bound ligands. We show that the proposed models work robustly and with high accuracy (ACC > 0.9) for determining the category of molecules derived from docking-based and crystallized poses. Furthermore, the models are also capable of determining the molecular category of ligands with dual opposite functions on different NRs (i.e., working as an agonist in one NR target, whereas functioning as an antagonist in another) with reasonable accuracy. The proposed method is expected to facilitate the determination of the molecular properties of ligands targeting the LBP of NRs with structural interpretation.

XLPFE: A Simple and Effective Machine Learning Scoring Function for Protein-Ligand Scoring and Ranking

Prediction of protein-ligand binding affinities is a central issue in structure-based computer-aided drug design. In recent years, much effort has been devoted to the prediction of the binding affinity in protein-ligand complexes using machine learning (ML). Due to the remarkable ability of ML methods in nonlinear fitting, ML-based scoring functions (SFs) can deliver much improved performance on a selected test set, such as the comparative assessment of scoring functions (CASF), when compared to the classical SFs. However, the performance of ML-based SFs heavily relies on the overall similarity of the training set and the test set. To improve the performance and transferability of an SF, we have tried to combine various features including energy terms from X-score and AutoDock Vina, the properties of ligands, and the statistical sequence-related information from either the binding site or the full protein. In conjunction with extreme trees (ET), an ML model, we have developed XLPFE, a new SF. Compared with other tested methods such as X-score, AutoDock Vina, ΔvinaXGB, PSH-ML, or CNN-score, XLPFE achieves consistently better scoring and ranking power for various types of protein-ligand complex structures beyond the CASF, suggesting that XLPFE has superior transferability. In particular, XLPFE performs better with metalloenzymes. With its faster speed, improved accuracy, and better transferability, XLPFE could be usefully applied to a diverse range of protein-ligand complexes.

The impact of cross-docked poses on performance of machine learning classifier for protein-ligand binding pose prediction

Structure-based drug design depends on the detailed knowledge of the three-dimensional (3D) structures of protein-ligand binding complexes, but accurate prediction of ligand-binding poses is still a major challenge for molecular docking due to deficiency of scoring functions (SFs) and ignorance of protein flexibility upon ligand binding. In this study, based on a cross-docking dataset dedicatedly constructed from the PDBbind database, we developed several XGBoost-trained classifiers to discriminate the near-native binding poses from decoys, and systematically assessed their performance with/without the involvement of the cross-docked poses in the training/test sets. The calculation results illustrate that using Extended Connectivity Interaction Features (ECIF), Vina energy terms and docking pose ranks as the features can achieve the best performance, according to the validation through the random splitting or refined-core splitting and the testing on the re-docked or cross-docked poses. Besides, it is found that, despite the significant decrease of the performance for the threefold clustered cross-validation, the inclusion of the Vina energy terms can effectively ensure the lower limit of the performance of the models and thus improve their generalization capability. Furthermore, our calculation results also highlight the importance of the incorporation of the cross-docked poses into the training of the SFs with wide application domain and high robustness for binding pose prediction. The source code and the newly-developed cross-docking datasets can be freely available at https://github.com/sc8668/ml_pose_prediction and https://zenodo.org/record/5525936 , respectively, under an open-source license. We believe that our study may provide valuable guidance for the development and assessment of new machine learning-based SFs (MLSFs) for the predictions of protein-ligand binding poses.

Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises

There is an urgent need to identify new therapies that prevent SARS-CoV-2 infection and improve the outcome of COVID-19 patients. This pandemic has thus spurred intensive research in most scientific areas and in a short period of time, several vaccines have been developed. But, while the race to find vaccines for COVID-19 has dominated the headlines, other types of therapeutic agents are being developed. In this mini-review, we report several databases and online tools that could assist the discovery of anti-SARS-CoV-2 small chemical compounds and peptides. We then give examples of studies that combined in silico and in vitro screening, either for drug repositioning purposes or to search for novel bioactive compounds. Finally, we question the overall lack of discussion and plan observed in academic research in many countries during this crisis and suggest that there is room for improvement.